Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2199 - Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer


10 Oct 2016


Poster display


Sibylle Loibl


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


S. Loibl1, A. Demichele2, N.M. Turner3, M. Cristofanilli4, S. Loi5, S. Verma6, H. Bhattacharyya7, Z. Ke8, C. Giorgetti9, C.H. Bartlett10, S. Iyer11, M. Colleoni12, N. Masuda13, S. Im14, N. Harbeck15

Author affiliations

  • 1 Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 2 Medicine, University of Pennsylvania-Perelman Center for Advanced Medicine, 19104 - Philadelphia/US
  • 3 Molecular Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 4 Feinberg School Of Medicine, Robert. H. Lurie Cancer Center of Northwestern University, Chicago/US
  • 5 Division Of Cancer Medicine, Peter MacCallum Cancer Centre, 3002 - East Melbourne/AU
  • 6 Tom Baker Cancer Centre, Department Of Oncology, University of Calgary, Calgary/CA
  • 7 Statistics, Pfizer,Inc, New York/US
  • 8 Biostatistics, Pfizer, Inc, La Jolla/US
  • 9 Clinical Development, Pfizer, Inc, Milano/IT
  • 10 Global Medical, Pfizer,Inc, New York/US
  • 11 Global Outcomes & Evidence, Pfizer, Inc, New York/US
  • 12 Medical Oncology, European Institute of Oncology (EIO), 20141 - Milan/IT
  • 13 Surgery, National Hospital Organization Osaka National Hospital, 540-0006 - Osaka/JP
  • 14 Internal Medicine, Seoul National University Hospital, Seoul/KR
  • 15 Breast Center, University of Munich, 81377 - Munich/DE


Abstract 2199


The present analyses compares patient reported general health status between palbociclib plus fulvestrant and fulvestrant alone in HR + , HER2- metastatic breast cancer.


Patients in PALOMA -3 study (NCT 01942135; Turner et al. NEJM 2016) were randomized to palbociclib plus fulvestrant (n= 347) or placebo plus fulvestrant (n= 174). Patient-reported outcomes were assessed at baseline, on day 1 of each cycle until cycle 4 and every alternate cycle from cycle 6 until end of treatment using EQ-5D, a standardized measure of health status that consists of a descriptive system comprising 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression rated at 3 levels (no, some, or extreme problems) and a single index score for health status (range 0 [dead] to 1 [full health]) calculated using a standard algorithm. In addition, a visual analog scale (VAS) measured self-rated health status from ‘0’ (worst imaginable) to ‘100’ (best imaginable). Repeated measures mixed-effects analyses were performed to compare overall index and VAS scores between treatments, controlling for baseline.


Completion rates at baseline were ≥85% in each group. The mean (SD) scores at baseline were comparable between palbociclib plus fulvestrant and fulvestrant alone for the VAS (72.9 [17.22] vs 70.3 [19.87]) and the EQ-5D index scores (0.73 [0.23]) vs (0.71 [0.23]). General health status assessed by VAS was found to be maintained from baseline and no significant difference in overall EQ-5D VAS scores was observed between the treatment arms. The proportion of patients reporting the presence of a problem at baseline was similar for palbociclib plus fulvestrant and fulvestrant, respectively: mobility (28% vs 32%), self-care (9% vs 9%), usual activities (38% vs 45%), pain (67% vs 67%), and anxiety/depression (52% vs 61%). The overall mean EQ-5D index scores on treatment was significantly greater (p 


Addition of palbociclib to fulvestrant was associated with significantly higher on treatment EQ-5D index scores compared to fulvestrant alone.

Clinical trial identification


Legal entity responsible for the study



Pfizer, Inc


S. Loibl: Research and funding and honoraria to institution from GlaxoSmithKline; Novartis; Roche Pharma AG; Pfizer;Celgene, Amgen, and most other pharmaceutical companies. A. Demichele: Participant on Advisory Board sponsored by Pfizer. N.M. Turner: Consultant/ Advisory role and receives honoraria from AstraZeneca; Pfizer; Roche Pharma AG. M. Cristofanilli: honoraria - Agendia; Cynvenio Biosystems; Dompé Farmaceutici Consulting/Advisory role-Cynvenio Biosystems; Dompé Farmaceutici; Newomics Speaker's bureau- Agendia; NanoString Technologies. S. Loi: Affiliated Institute receives research funding from PharmaSea. S. Verma: Advisory Board Panel Member for Pfizer, Roche, AZ, Novartis,Amgen, Eisai,BMS, Eli Liily and Merck. H. Bhattacharyya: Pfizer employee and stockholder.

Z. Ke, C. Giorgetti, C.H. Bartlett: Pfizer Employee and Stockholder. S. Iyer: Employee and shareholder/stock options owner of Pfizer, Inc .M. Colleoni: Honararia - Novartis Advisory Role - Boehringer, Astra Zeneca, Pierre Fabre, Pfizer. N. Masuda: Personal Fees, Honararia; Research funding -Chugai, Astra zeneca, kyowa krin Research funding- Pfizer, Novartis, Eli Lilly. S-A. Im: Grant - Astra Zeneca Advisory Role- AZ, Roche, Novartis. N. Harbeck: Honoraria -Amgen; Celgene; NanoString Technologies; Novartis; Pfizer; Roche Consulting/Advosory role -AstraZeneca; Celgene; Genomic Health; Novartis; Roche/Genentech; Sandoz; Wilex Research funding -Boehringer Ingelheim; Novartis; Pfizer;

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings